# Understanding the Tumor Microenvironmental Mechanisms Driving Immunotherapy Resistance in Colorectal Cancer Liver Metastases

## TL;DR

This review explores how the liver's tumor microenvironment helps colorectal cancer spread and resist immunotherapy, and discusses new strategies to overcome this resistance.

## Contribution

The paper synthesizes recent findings on the hepatic metastatic microenvironment and novel therapeutic approaches for colorectal cancer.

## Key findings

- The liver's tumor microenvironment promotes immune tolerance and supports metastasis.
- Immunosuppressive cells and factors in the liver limit the effectiveness of immunotherapy.
- Combination therapies and TME-targeting approaches are being explored to improve treatment outcomes.

## Abstract

Colorectal cancer (CRC) is the second deadliest cancer worldwide, being the presence of metastasis, mainly in the liver, a major contributor to high mortality rates in affected patients. The tumor microenvironment (TME)—comprised of interacting endothelial, stromal, and immune cells—plays a critical role in creating a supportive niche for tumor cell colonization and immune evasion and, thus, the establishment of metastases. The liver’s intrinsic nature further facilitates the development of immune tolerance, mediated by regulatory T cells, myeloid-derived suppressor cells, and soluble factors such as anti-inflammatory cytokines, which together dampen antitumor immune responses. This immunosuppressive milieu contributes significantly to resistance to immune checkpoint inhibitors, limiting the efficacy of immunotherapy in metastatic CRC. Deciphering the complex crosstalk between metastatic CRC cells and TME within the liver is essential for developing novel, effective immunotherapeutic approaches. Several strategies to overcome this lack of response are under research, including combination therapies, novel compounds, and approaches that target TME components. The scope of this review is to synthesize recent advances in the characterization of the hepatic metastatic microenvironment and emerging therapeutic approaches aimed at overcoming immune resistance in CRC liver metastases.